Analysis of efficacy and safety of vismodegib therapy in patients with advanced basal cell carcinoma – real world multicenter cohort study

BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non‐melanoma skin cancer. The basis of treatment is surgical resection. The treatment of locally advanced and metastatic disease is currently based on sonidegb or vismodegib, small molecule inhibitors of the hedgehog signalling pathway. OBJ...

Descripción completa

Detalles Bibliográficos
Autores principales: Słowińska, M., Dudzisz‐Śledź, M., Sobczuk, P., Łasińska, I., Pietruszka, A., Cybulska‐Stopa, B., Kowalczyk, A., Świtaj, T., Czarnecka, I., Koseła‐Paterczyk, H., Rogala, P., Paluchowska, E., Składowski, K., Mackiewicz, J., Rutkowski, P., Owczarek, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles and Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541446/
https://www.ncbi.nlm.nih.gov/pubmed/35279879
http://dx.doi.org/10.1111/jdv.18070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541446/
https://www.ncbi.nlm.nih.gov/pubmed/35279879
http://dx.doi.org/10.1111/jdv.18070

Ejemplares similares